Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Doripenem→

Doripenem Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
148016-81-3
PubChem CID
73303
Molecular formula
C15H24N4O6S2
Molecular weight
420.5 g/mol
Drug class
Carbapenem beta-lactam antibacterialbroad-spectrum parenteral antibiotic
Mechanism of action
Binds penicillin-binding proteins and inhibits bacterial cell-wall peptidoglycan synthesis, resulting in bactericidal activity against susceptible Gram-positive, Gram-negative and anaerobic organisms.
Indications / reported uses
  • Treatment of complicated intra-abdominal infections and complicated urinary-tract infections, including pyelonephritis, caused by susceptible bacteria where doripenem is authorised; current availability and restricted use due to mortality signal in ventilator-associated pneumonia must be considered

Sources: US FDA — Doribax prescribing information and safety restrictions · NLM MeSH — Doripenem · FDA product information

Identification source: PubChem record (CID 73303). The linked PubChem record is provided for identity reference. Confirm the exact salt, hydrate, isomer, mixture, or product form against authoritative source documentation when defining the assessment scope.

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Doripenem Environmental Risk Assessment (ERA) (the Doripenem ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.